Spevigo▼ (spesolimab)
This page is intended to provide reference information for UK members of the public, patients prescribed Spevigo 450 mg (spesolimab) and their carers. This information is not intended to replace the advice of a healthcare professional.
Patient Information Leaflet
The Patient Information Leaflet is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using this medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
If you are in the United Kingdom, click the link below to access this information.
Patient Information Leaflet (UK)
Summary of Product Characteristics
The Summary of Product Characteristics (SmPC) tells healthcare professionals, such as doctors, pharmacists and nurses, how to prescribe and use this medicine correctly. The information in the Patient Information Leaflet and Summary of Product Characteristics are not intended to replace the advice of a healthcare professional.
Click the link below to access this information.
Summary of Product Characteristics
Public Assessment Report
The Public Assessment Report (PAR) provides public information on a medicine, including how it was assessed by the MHRA.
If you are in the United Kingdom, click the link below to access this information.
Public Assessment Report (UK)
NP-GB-105303 | December 2024
